



Norwegian Cruise Line Holdings Ltd. established the SailSAFE Global Health and Wellness Council (“Council”) to provide expert advice on the implementation, compliance with and continuous improvement of the Company’s SailSAFE™ Health and Safety Program. The Council will complement the work of the Healthy Sail Panel to prepare for the safe resumption of cruise voyages and will continuously evaluate and identify ways to evolve health and safety standards utilizing the best technologies and information available. The Council is cross-functional, diverse and extensively experienced, comprised of six experts at the forefront of their fields and led by Chairman of the Council, Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration.



NORWEGIAN CRUISE LINE
HOLDINGS LTD.

FOR MORE INFORMATION VISIT NCLHLTD.COM



DR. SCOTT GOTTLIEB, CHAIRMAN OF THE COUNCIL

Scott Gottlieb, M.D. is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery and expanding consumer choice and safety. Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He is a member of the board of directors of Pfizer Inc. and Illumina, Inc. Dr. Gottlieb also currently serves as a Co-Chair of the Healthy Sail Panel, a collaboration between the Company and Royal Caribbean Group to help guide the industry’s way forward in response to COVID-19.



DR. STEPHEN OSTROFF

Dr. Ostroff was Acting Commissioner of the FDA from 2015 to 2016, and prior to that role he served as the FDA’s chief scientist. He joined FDA in 2013 as chief medical officer in the Center for Food Safety and Applied Nutrition and senior public health advisor to FDA’s Office of Foods and Veterinary Medicine. Before his time at the FDA, Dr. Ostroff served as deputy director of the National Center for Infectious Diseases at the CDC. He retired from the Commissioned Corps of the U.S. Public Health Service at the rank of Rear Admiral (Asst. Surgeon General). Dr. Ostroff also served as director of the Bureau of Epidemiology and acting physician general of Pennsylvania.



DR. PHYLLIS KOZARSKY

Dr. Kozarsky is a Professor Emerita in infectious diseases at Emory University having been a clinician, researcher, and teacher for over 35 years. She was the catalyst behind the building of Emory’s serious communicable disease unit that cares for patients with highly transmissible diseases such as the Ebola virus. Dr. Kozarsky has been a consultant to the CDC for over 20 years including in the Division of Global Migration and Quarantine, where she was chief of travelers’ health and the long-time editor of Health Information for International Travel. She has received a number of honors and awards from US Health and Human Services and the CDC for her involvement in responses to outbreaks such as anthrax, SARS, and H1N1. Dr. Kozarsky has also been a medical consultant for several Fortune 500 companies and the White House medical unit. Dr. Kozarsky was a founder of the International Society of Travel Medicine and the GeoSentinel Surveillance Network, where she is the senior advisor.



KATE WALSH, PH.D

Dr. Walsh is Dean and E.M. Statler Professor at the School of Hotel Administration at Cornell University, and is recognized as a leader in education for the global hospitality industry. A professor of management, Dr. Walsh’s primary research is in organizational service design, leadership, and strategic investments in human capital. She has over 20 years of academic experience. In addition, Dr. Walsh has held a number of executive positions in hospitality human resources and is a former New York State certified public accountant. Dr. Walsh serves on the board of the American Hotel and Lodging Association.



JOHN Y. MASON

John Mason is the founder, CTO, and Chairman of The Sabre Companies, a group of operating entities specializing in the generation and application of chlorine dioxide. In his 35+ year career his core mission has been to minimize microbial contamination risk to both human and non-human health by developing value-adding technology for several industries. Since 1996, John and Sabre have worked extensively with several government agencies on various microbiological decontamination projects across Agricultural Production, Food Processing, Healthcare, and Defense, as well as continued work in the Oil and Gas Industry.